BRIEF—Relugolix hits endpoint in Phase III trial in pain associated with uterine fibroids

Positive top-line results have been reported from a Phase III trial of relugolix for the treatment of pain associated with uterine fibroids.

Relugolix met the primary endpoint of Takeda Pharmaceutical's trial, with 57.6% of women achieving marked improvement in pain symptoms compared to 3.1% of women receiving placebo.

The Japanese pharma major has granted Myovant, a company focused on women's health and endocrine diseases that was formed by Takeda and Roivant Sciences, an exclusive, worldwide license to develop and commercialize relugolix, excluding in Japan and certain other Asian countries.

Relugolix is also being evaluated by Myovant in two Phase III trials in women with heavy menstrual bleeding associated with uterine fibroids.